ClinicalTrials.gg
RecruitingNCT07694440CIPheRUpdated Oct 23, 2026

A Study of MZE782 in Adults With PKU

A Phase 2 interventional study of MZE782 and Placebo in Phenylketonuria (PKU), sponsored by Maze Therapeutics. Recruiting at 9 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Maze Therapeutics · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 23, 2026First sites in France and United KingdomEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 93 studies in Phenylketonurias with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Phenylketonurias · United States.

Planned enrollment
27th of 63
38 · median 33
Started
2026
with 4 others
Phase 2
13 of 93
1 open now
Primary completion
2027-12
later than 10 of 20 live
Registered
92nd of 93
by date

Among the 93 studies in Phenylketonurias with a site in United States, this one is the 27th largest by planned enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 10 of the 20 other live ones, and was the 92nd registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

16 of the 93 studies in Phenylketonurias with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Phenylketonurias with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU).

03

Conditions studied

  • Phenylketonuria (PKU)

Browse trials for

Keywords

  • PKU
  • Phenylketonuria
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males and females 18 to 75 years old
  • Confirmed diagnosis of PKU
  • Willing and able to keep diet and protein intake consistent during the study
  • For some study groups, is willing and able to stop certain PKU medications before starting study treatment
  • For some study groups, may need to meet additional blood phenylalanine level or background-treatment requirements
  • Meets minimum blood phenylalanine level requirements for study group

Key Exclusion Criteria:

  • Is pregnant, breastfeeding, or planning to become pregnant or conceive a child during the study
  • Medical conditions or abnormal test results that could make participation unsafe or make it difficult to complete study procedures or interpret study results
  • Has recently received another drug
  • Is unable to swallow tablets or tolerate oral medication

Other inclusion/exclusion criteria defined in protocol apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    MZE782 Low Dose (Cohort 1A)

    Drug: MZE782

  • Placebo comparator
    Placebo (Cohort 1A)

    Other: Placebo

  • Experimental
    MZE782 High Dose (Cohort 1B)

    Drug: MZE782

  • Placebo comparator
    Placebo (Cohort 1B)

    Other: Placebo

  • Experimental
    MZE782 High Dose (Cohort 2)

    Drug: MZE782

  • Placebo comparator
    Placebo (Cohort 2)

    Other: Placebo

Interventions

  • DrugMZE782

    Tablet, Low Dose

  • OtherPlacebo

    Tablet

  • DrugMZE782

    Tablet, High Dose

06

What researchers measure

Primary outcomes

  1. Safety and tolerability based on incidence of adverse events (AEs)

    Time frame: Week 0 to Week 17

  2. For Cohorts 1A and 1B: Absolute change in plasma Phe levels from Baseline to the mean of plasma Phe levels

    Time frame: Baseline and Weeks 2, 3, and 4

Secondary outcomes

  1. For Cohorts 1A and 1B, analyzed separately: Geometric mean plasma concentrations of MZE782

    Time frame: Weeks 1, 2, 3, 4, 8, and 13

  2. For Cohorts 1A and 1B, analyzed separately: Absolute and Percent change in plasma Phe levels from Baseline to the mean of plasma Phe levels

    Time frame: Baseline up to Week 13

  3. For Cohorts 1A and 1B, analyzed separately: Proportion of participants with mean plasma Phe levels ≤600 μMol/L, ≤360 μMol/L, and ≤120 μMol/L

    Time frame: Baseline and Weeks 2, 3, 4, 8, 10, and 13

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 10, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Feb 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first sites in France and United Kingdom
Show 3 added (1 United States, 1 France, 1 United Kingdom)
  • Ann and Robert H. Lurie Children's Hospital of Chicago · Chicago, United States
  • CHRU Hôpitaux de Tours - Hôpital Bretonneau · Tours, France
  • University College Hospital · London, United Kingdom
across 2 updates, Oct 8, 2026 – Oct 23, 2026
Eligibility
2 criteria edited
What changed in the criteria
  • EditedClinicalConfirmed diagnosis of PKU
  • EditedIs pregnant, breastfeeding, or planning to become pregnant or conceive a child during the study or within 90 days after the last dose
Oct 8, 2026
Show all 2 updates
  1. Oct 23, 2026
    2 sites added — first sites in France and United Kingdom
    Show 2 added (1 France, 1 United Kingdom)
    • CHRU Hôpitaux de Tours - Hôpital Bretonneau · Tours, France
    • University College Hospital · London, United Kingdom
  2. Oct 8, 2026
    1 site added
    Show site
    • Ann and Robert H. Lurie Children's Hospital of Chicago · Chicago, United States
    Eligibility 2 criteria edited
    What changed in the criteria
    • EditedClinicalConfirmed diagnosis of PKU
    • EditedIs pregnant, breastfeeding, or planning to become pregnant or conceive a child during the study or within 90 days after the last dose
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07694440
Lead sponsor
Maze Therapeutics
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Jun 23, 2026
Primary completion
Dec 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Maze Therapeutics
Contact
medicalinfo@mazetx.com
650-850-5075
Medical Director
study director · Maze Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion